Its high expression in ER + breast cancer cell lines was found to be associated with higher transcriptomic heterogeneity80 and was reversed upon treatment with KDM5 small molecule inhibitors, providing proof of concept that modulating the activity of epigenetic enzymes, can lead to improved responses to the standard of care treatment. Here, ESR1 is linked to breast carcinoma.